Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 307576, 7 pages
http://dx.doi.org/10.1155/2015/307576
Clinical Study

Modified Weekly Cisplatin-Based Chemotherapy Is Acceptable in Postoperative Concurrent Chemoradiotherapy for Locally Advanced Head and Neck Cancer

1Division of Hematology and Oncology, Show Chwan Memorial Hospital, Changhua, Taiwan
2Faculty of Medicine, National Yang Ming University, Taipei, Taiwan
3Program in Molecular Medicine, School of Life Sciences, National Yang-Ming University, Taipei, Taiwan
4Division of Hematology and Oncology, Department of Medicine, Taipei Veterans General Hospital, No. 201, Section 2, Shih-Pai Road, Taipei 112, Taiwan
5Department of Medicine, Taipei City Hospital, Yang-Ming Branch, Taipei, Taiwan
6Department of Oncology Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
7Department of Otolaryngology, Taipei Veterans General Hospital, Taipei, Taiwan
8Institute of Clinical Medicine, National Yang Ming University, Taipei, Taiwan

Received 4 September 2014; Revised 13 November 2014; Accepted 14 November 2014

Academic Editor: Yun Yen

Copyright © 2015 Hsueh-Ju Lu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background. Triweekly cisplatin-based postoperative concurrent chemoradiotherapy (CCRT) has high intolerance and toxicities in locally advanced head and neck cancer (LAHNC). We evaluated the effect of a modified weekly cisplatin-based chemotherapy in postoperative CCRT. Methods. A total of 117 patients with LAHNC were enrolled between December 2007 and December 2012. Survival, compliance/adverse events, and independent prognostic factors were analyzed. Results. Median follow-up time was 30.0 (3.1–73.0) months. Most patients completed the entire course of postoperative CCRT (radiotherapy ≥ 60 Gy, 94.9%; ≥6 times weekly chemotherapy, 75.2%). Only 17.1% patients required hospital admission. The most common adverse effect was grade 3/4 mucositis (28.2%). No patient died due to protocol-related adverse effects. Multivariate analysis revealed the following independent prognostic factors: oropharyngeal cancer, extracapsular spread, and total radiation dose. Two-year progression-free survival and overall survival rates were 70.9% and 79.5%, respectively. Conclusion. Modified weekly cisplatin-based chemotherapy is an acceptable regimen in postoperative CCRT for LAHNC.